Jefferies analyst Akash Tewari maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and rai

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 poi

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday. Shares of A

On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pha

BioMarin Pharmaceutical and Ascendis Pharma settled global patent disputes over Yuviwel, granting Bi

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that it has entered into binding terms wi

BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMar

Agreement Resolves all Pending Patent-Related Proceedings Between BioMarin and Ascendis SAN RAFAEL,

Bank of New York Mellon Corp bought a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ: B

ADAR1 Capital Management LLC acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) dur

BMRN's $490M Alesta deal adds ALE1, a potential oral HPP therapy, broadening its rare bone disease p

BioMarin will acquire Alesta Therapeutics for $275 million upfront, and up to an additional $215 mil

Wall Street analysts change outlook on top stocks, including BIDU and BMO. See their ratings and pri

Markets turned south again Wednesday as surging yields and geopolitical fears rattled investors, but

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Chec

BMO Capital analyst David Lebowitz initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) wi

BioMarin Pharmaceutical agrees to acquire Alesta Therapeutics for $275 million upfront, securing ALE

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BioMarin has entered into a definiti

BioMarin to pay $275 million upfront, plus additional payments upon achievement of development and r

Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Over

Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight a

Here is how BioMarin Pharmaceutical (BMRN) and Cardinal Health (CAH) have performed compared to thei

BioMarin, Invesco, Centene, HPE and Gibraltar Industries stand out as undervalued stocks with low pr

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider

The mean of analysts' price targets for BioMarin (BMRN) points to a 28.2% upside in the stock. While

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Tr

BioMarin Pharmaceutical NASDAQ: BMRN outlined its growth strategy, integration plans for Amicus Ther

SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today

Canaccord Genuity analyst Whitney Ijem maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy

Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Ov

BioMarin stock rises on Q2 sales beat and raises 2026 outlook, highlighting strong Voxzogo growth, A

Oppenheimer analyst Leland Gershell maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outper

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN

BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript

While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performe

BioMarin Pharmaceutical (NASDAQ:BMRN) raises FY2026 Adj EPS guidance from $4.85-$5.05 to $4.90-$5.10

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $1.20 per share which beat the

Citigroup analyst Eric Joseph maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and rais

The sNDA submission was supported by substantial long-term safety and efficacy data from three ongoi

RBC Capital analyst Luca Issi maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perfo

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced new data from studies of VOXZOGO® (vosoritide)

BioMarin stock climbed after Phase 3 VOXZOGO data showed significant growth improvements in children

B of A Securities analyst Jason Zemansky maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a B

Citigroup analyst Eric Joseph initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) with a

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN

ENERGY 3 is a Phase 3 multicenter randomized (2:1) controlled open-label clinical trial designed to

Goldman Sachs analyst Salveen Richter reinstates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neu